BiotechTube

Treatment with oral sucrosomial iron + Treatment with intravenous iron

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Anemia

Conditions

Anemia, Iron Deficiency Anemia

Trial Timeline

Dec 31, 2025 → Jun 30, 2027

NCT ID
NCT07287371

About Treatment with oral sucrosomial iron + Treatment with intravenous iron

Treatment with oral sucrosomial iron + Treatment with intravenous iron is a approved stage product being developed by Pharmanutra for Anemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07287371. Target conditions include Anemia, Iron Deficiency Anemia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT07287371ApprovedRecruiting

Competing Products

20 competing products in Anemia

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
84
KER-047Keros TherapeuticsPhase 2
44
LY2787106Eli LillyPhase 1
33
R744 + R744Chugai PharmaceuticalPhase 3
77
epoetin beta + placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
77
darbepoetin alfaAmgenPhase 3
76
PrasugrelDaiichi SankyoPhase 1
33
Prasugrel + PlaceboDaiichi SankyoPhase 2
52
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaPhase 1
33
RoxadustatAstellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 1
33
Roxadustat + PlaceboAstellas PharmaPhase 3
77
RoxadustatAstellas PharmaPre-clinical
23
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77

Other Products from Pharmanutra

Ferric Maltol (Feraccru®)Approved
80